{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:03:21Z","timestamp":1790528601587,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Faculty of Medicine, University of Tuebingen","award":["1830-0-0"],"award-info":[{"award-number":["1830-0-0"]}]},{"name":"Faculty of Medicine, University of Tuebingen","award":["1961-0-0"],"award-info":[{"award-number":["1961-0-0"]}]},{"name":"Delfin"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.yexcr.2014.10.018","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T21:47:10Z","timestamp":1414705630000},"page":"97-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma"],"prefix":"10.1016","volume":"331","author":[{"given":"Carmen","family":"Nagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorin","family":"Armeanu-Ebinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dewerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Warmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2014.10.018_bib1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/mpo.10178","article-title":"Adult type vs. childhood hepatocellular carcinoma\u2014are they the same or different lesions? Biology, natural history, prognosis, and treatment","volume":"39","author":"Czauderna","year":"2002","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.yexcr.2014.10.018_bib2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/pbc.22893","article-title":"Critical review of controversial issues in the management of advanced pediatric liver tumors","volume":"56","author":"Gupta","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.yexcr.2014.10.018_bib3","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/cncr.11292","article-title":"Fibrolamellar hepatocellular carcinoma in children and adolescents","volume":"97","author":"Katzenstein","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.yexcr.2014.10.018_bib4","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2002.06.102","article-title":"Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group","volume":"20","author":"Czauderna","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2014.10.018_bib5","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.2002.06.155","article-title":"Hepatocellular carcinoma in children and adolescents: results from the pediatric oncology group and the children\u05f3s cancer group intergroup study","volume":"20","author":"Katzenstein","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2014.10.018_bib6","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.yexcr.2014.10.018_bib7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/pbc.23295","article-title":"Sorafenib and cisplatin\/doxorubicin (PLADO) in pediatric hepatocellular carcinoma","volume":"58","author":"Schmid","year":"2012","journal-title":"Pediatr. Blood Cance"},{"key":"10.1016\/j.yexcr.2014.10.018_bib8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/11595360-000000000-00000","article-title":"Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin","volume":"25","author":"Ho","year":"2011","journal-title":"BioDrugs"},{"key":"10.1016\/j.yexcr.2014.10.018_bib9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.2165\/11596690-000000000-00000","article-title":"Epigenetic-based therapies in cancer: progress to date","volume":"71","author":"Song","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.yexcr.2014.10.018_bib10","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1053\/j.gastro.2011.03.006","article-title":"Targeted therapies for hepatocellular carcinoma","volume":"140","author":"Villanueva","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.yexcr.2014.10.018_bib11","doi-asserted-by":"crossref","first-page":"e38223","DOI":"10.1371\/journal.pone.0038223","article-title":"Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma","volume":"7","author":"Armeanu-Ebinger","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2014.10.018_bib12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","volume":"407","author":"Adnane","year":"2006","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.yexcr.2014.10.018_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.yexcr.2014.10.018_bib14","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Kane","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2014.10.018_bib15","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1478-3231.2011.02729.x","article-title":"Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice","volume":"32","author":"Eicher","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/j.yexcr.2014.10.018_bib16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/bjc.2012.539","article-title":"Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts","volume":"108","author":"Eicher","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yexcr.2014.10.018_bib17","first-page":"1","article-title":"Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma","volume":"67","author":"Doi","year":"1976","journal-title":"Gann"},{"key":"10.1016\/j.yexcr.2014.10.018_bib18","first-page":"809","article-title":"Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma","volume":"74","author":"Pietsch","year":"1996","journal-title":"Lab. Investig."},{"key":"10.1016\/j.yexcr.2014.10.018_bib19","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/hep.26255","article-title":"alphaB-Crystallin complexes with 14-3-3zeta to induce epithelial\u2013mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma","volume":"57","author":"Huang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.yexcr.2014.10.018_bib20","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1053\/j.gastro.2012.08.032","article-title":"Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice","volume":"143","author":"Zhang","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.yexcr.2014.10.018_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11010-013-1695-6","article-title":"Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt\/beta-catenin signaling","volume":"381","author":"Wei","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.yexcr.2014.10.018_bib22","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2014.10.018_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1535-7163.MCT-10-0544","article-title":"Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma","volume":"10","author":"Nagai","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.yexcr.2014.10.018_bib24","doi-asserted-by":"crossref","first-page":"e35826","DOI":"10.1371\/journal.pone.0035826","article-title":"Receptor tyrosine kinases activate canonical WNT\/beta-catenin signaling via MAP kinase\/LRP6 pathway and direct beta-catenin phosphorylation","volume":"7","author":"Krejci","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2014.10.018_bib25","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2010.1672","article-title":"Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial","volume":"304","author":"Abou-Alfa","year":"2010","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.yexcr.2014.10.018_bib26","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/pbc.24171","article-title":"Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: Stable radiographic disease with decreased AFP","volume":"59","author":"Marsh","year":"2012","journal-title":"Pediatr. Blood Cancer"}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482714004790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482714004790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:14:11Z","timestamp":1762146851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482714004790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0014482714004790"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2014.10.018","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2014.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}